Launching prescription medicines excellently – achieving optimal commercial performance that reflects a medicine’s value and ...

Novartis is set to acquire Myricx Bio, paying $1.1bn upfront, with up to $400m in potential milestone payments. The acquisition would strengthen Novartis’ oncology pipeline and advance next-generation ...

Klick Health, a global, independent commercialisation partner for life sciences, has acquired Oxford PharmaGenesis, a ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has announced plans to deepen its collaboration with the US Food and Drug Administration (FDA) to enhance patient access to ...

Every year, ASCO arrives with a theme. Most quietly disappear into the background by the end of the opening session, ...

Key takeaways from the Patient Centricity and Engagement conference, exploring how trust, inclusion and meaningful ...

Women in Healthcare Leadership podcast series. Now on its fourth series, “Hear from Her” has established itself globally as ...

Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and ...

For pharma, its AI progress appears to be slowed by a methodical procession of AI adoption through a series of chicanes.

Roche’s Enspryng (satralizumab), a thyroid eye disease (TED) treatment, has been accepted by the FDA and given priority ...

Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies ...

Zymeworks, a biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of ...